EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antrodia cinnamomea Formula Suppresses Prostate Cancer Progression via Immune Modulation and PD-1/PD-L1 Pathway Inhibition

Ming-Yen Tsai iD, Chung-Kuang Lu, Li-Hsin Shu, Hung-Te Liu, Yu-Huei Wu, Yu-Shih Lin, Yao-Hsu Yang, Wei-Tai Shih iD, I-Yun Lee, Yu-Heng Wu, Ching-Yuan Wu

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ming-Yen Tsai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, B7-H1 Antigen, Antrodia, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council (TW), Chiayi Chang Gung Memorial Hospital, Chang Gung Memorial Hospital (Chiayi).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer remains a significant global health challenge, necessitating the development of novel therapeutic approaches. This study investigated the therapeutic potential of the Antrodia cinnamomea formula (XIANZHIFANG formula, XZF), comprising Antrodia cinnamomea, Sanghuangporus sanghuang, Ganoderma lucidum, Ganoderma sinense, and Inonotus obliquus, in prostate cancer treatment. HPLC analysis confirmed the presence of key triterpenoids, including Antcin A, B, C, K, and Zhankuic acid B, C, and 4,7-dimethoxy-5-methyl-1,3-benzodioxole. Cytotoxicity assays demonstrated that XZF (50–200 μg/mL) exhibited selective activity, maintaining viability in non-cancerous 293T-cells while enhancing the viability of activated CD8+ and CD4+ T-cells in a dose-dependent manner. XZF significantly reduced PD-1 expression in CD8+ T-cells but not in CD4+ T-cells and inhibited the PD-L1/PD-1 interaction, achieving 93% inhibition at 200 μg/mL. Furthermore, when combined with atezolizumab (1 μg/mL), XZF demonstrated complete blockade of PD-L1/PD-1 interaction. In prostate cancer cells, XZF exhibited differential antiproliferative effects. In PC-3 cells, XZF significantly reduced viability across a concentration range of 25–200 μg/mL, whereas DU145 cells showed only partial inhibition at higher concentrations (100–200 μg/mL). LNCaP cells exhibited a dose-dependent reduction in viability, mirroring the response pattern of PC-3 cells. Conditioned medium from XZF-treated macrophages, particularly human THP-1 cells, significantly suppressed the viability and migration of prostate cancer cells in a dose-dependent manner. Notably, the conditioned medium from XZF-treated THP-1 cells exhibited a stronger inhibitory effect on prostate cancer cell viability and migration compared to murine RAW 264.7 macrophages. These findings indicate that XZF exerts its therapeutic potential through multiple mechanisms, including direct antiproliferative effects on cancer cells, enhancement of T-cell responses, modulation of immune checkpoint pathways, and macrophage-mediated suppression of prostate cancer cell survival and migration. The pronounced effects observed in human macrophage models suggest a promising avenue for further investigation in clinical settings, particularly in combination with existing immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsB7-H1 AntigenAntrodiaProgrammed Cell Death 1 ReceptorDrugs, Chinese HerbalMaleHumansCell Line, TumorAnimalsSignal TransductionCD4-Positive T-LymphocytesMiceCD8-Positive T-LymphocytesCell SurvivalDisease ProgressionCell Proliferation

Stichwörter der Autor:innen

PD-1PD-L1T-cellsXIANZHIFANG formulamacrophageprostate cancer

Substanzen

B7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 ReceptorDrugs, Chinese HerbalPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.
  • Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613016, Taiwan.
  • Department of Pharmacy, Chiayi Chang Gung Memorial Hospital, Chiayi 613016, Taiwan.
  • School of Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
  • Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi 613016, Taiwan.
  • Institute of Communications Engineering, The National Yang Ming Chiao Tung University, Hsinchu City 300093, Taiwan.

ORCID-Profile: Ming-Yen Tsai, Wei-Tai Shih

Förderung

  • National Science and Technology Council (TW)
  • Chiayi Chang Gung Memorial Hospital
  • Chang Gung Memorial Hospital (Chiayi)

Zitieren

APA

Tsai, M. Y., Lu, C. K., Shu, L. H., Liu, H. T., Wu, Y. H., Lin, Y. S., Yang, Y. H., Shih, W. T., Lee, I. Y., Wu, Y. H., & Wu, C. Y. (2025). Antrodia cinnamomea Formula Suppresses Prostate Cancer Progression via Immune Modulation and PD-1/PD-L1 Pathway Inhibition. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062684

Vancouver

Tsai MY, Lu CK, Shu LH, Liu HT, Wu YH, Lin YS, et al. Antrodia cinnamomea Formula Suppresses Prostate Cancer Progression via Immune Modulation and PD-1/PD-L1 Pathway Inhibition. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062684

BibTeX
@article{Tsai2025,
  author = {Tsai, Ming-Yen and Lu, Chung-Kuang and Shu, Li-Hsin and Liu, Hung-Te and Wu, Yu-Huei and Lin, Yu-Shih and Yang, Yao-Hsu and Shih, Wei-Tai and Lee, I-Yun and Wu, Yu-Heng and Wu, Ching-Yuan},
  title = {Antrodia cinnamomea Formula Suppresses Prostate Cancer Progression via Immune Modulation and PD-1/PD-L1 Pathway Inhibition},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062684}
}
Kostenlos starten →